fbpx Skip to main content
 

Search

Oral Cavity Oropharyngeal Cancer

Partnership to Intercept Oral Cavity/Oropharyngeal Cancer

The Disease Interception Accelerator established a partnership with UbiVac, a privately held, clinical-stage, immuno-oncology company for the development of an immunotherapy that is intended to intercept oral cavity/oropharyngeal cancer.

World Without Disease Accelerator

World Without Disease Accelerator

istock
 

Oncology

Oncology

Human lung bronchioalveolar carcinoma cell

Disease Interception Accelerator

Disease Interception Accelerator

Partnerships

Partnerships

Wendy Olsen, lincs
Wendy Olsen, lincs